瑞替普酶与尿激酶治疗急性心肌梗死的疗效比较  

Comparing Efficacy of Reteplase with Urokinase on Acute Myocardial Infarction

作　　者：黄新平[1] 孙琳[1] 李慧娟[1] 洪云飞[2] 张荣华[2] 

机构地区：[1]大理学院昆明附属医院心内科,云南昆明650011 [2]大理学院省红会教学医院心内科,云南昆明650021

出　　处：《大理学院学报（综合版）》2008年第10期24-26,共3页Journal of Dali University

摘　　要：目的:观察瑞替普酶与国产尿激酶治疗急性心肌梗死(AMI)的临床疗效和副作用。方法:将172例AMI病人随机分两组。瑞替普酶组94例,给予瑞替普酶20mU,分2次,每次10mU,间隔30min静脉推注;尿激酶组78例,先予尿激酶100×104U静脉推注,后予100×104U溶于5%GS150ml内,30min内静脉滴注。两组均用注射用低分子肝素皮下注射,其余治疗也相同。结果:瑞替普酶组与尿激酶组的血管开通率、开通时间分别为85%与63%;(0.80±0.52)h与(1.36±0.55)h(P<0.05);CK和CK-MB峰值及峰值时间:两组差异无显著性(P>0.05);副作用:轻度出血率在瑞替普酶组与尿激酶组分别为4%与9%(P<0.05)。结论:瑞替普酶治疗AMI的疗效优于尿激酶,且副作用小。Objective： To observe the efficacy and side-effects of Reteplase and Urokinase in treating the patients with acute myocardial infarction （AMI）. Methods： 172 patients with AMI was randomly divided into Reteplase group （R group,n=94） and Urokinase group（U group,n=78）. In R group, 20MU of Reteplase was given with 10MU each, 30min. interval in intravenous injection. In U group, Urokinase was given first with 100×10^4U in injection and then 100×10^4 U in 5 %G.S 150ml intravenous drip. Treatment was the same for the other two groups, excepting the use of heparin. Results： The patency rates and time of patency in R group and U group were 85% vs 63%（P〈0.05 ）, （0.80±0.52） h vs （1.36 ±0.55 ） h （P〈 0.05 ） respectively. Mild bleeding was 4% vs 9% （P〈0.05）. There was no difference in peak values of CK, CK-MB and their times between the two groups （P〉0.05）. Conclusions： The efficacy of Reteplase was better than that of Urokinase with fewer side-effects.

关 键 词：瑞替普酶 尿激酶 心肌梗死 

分 类 号：R541[医药卫生—心血管疾病]